Richard Klausner - 14 Jun 2024 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Role
Director
Signature
/s/ Matthew Lang, as Attorney-in-Fact
Issuer symbol
LYEL
Transactions as of
14 Jun 2024
Net transactions value
$0
Form type
4
Filing time
17 Jun 2024, 16:15:57 UTC
Previous filing
08 Sep 2023
Next filing
18 Mar 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding LYEL Common Stock 2,967,834 14 Jun 2024 Direct
holding LYEL Common Stock 685,365 14 Jun 2024 Grantor F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LYEL Option (right to buy) Award $0 +130,000 $0.000000 130,000 14 Jun 2024 Common Stock 130,000 $2.36 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of 245,515 shares held by The Ariella Klausner Delaware Trust, 194,335 shares held by The Eli Klausner Delaware Trust and 245,515 shares held by The Olivia Klausner Delaware Trust. The Reporting Person is a grantor of each of the trusts and disclaims beneficial ownership of all shares held by the trusts except to any pecuniary interest therein. The JTC Trust Company (Delaware) Limited is the trustee of each of the trusts.
F2 The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 14, 2024 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 14, 2024, subject to the Reporting Person providing continuous service through such date.